Zoetis Inc. $ZTS Stake Lessened by Alpine Woods Capital Investors LLC

Key Points

• Alpine Woods Capital Investors LLC decreased its interest in Zoetis Inc. by 53.8%, holding 8,725 shares after selling 10,170 shares during the second quarter.
• Several institutional investors acquired new stakes in Zoetis, including Nova Wealth Management and Saudi Central Bank, highlighting ongoing investment interest in the company.
• Zoetis reported a quarterly EPS of $1.76, exceeding expectations, and announced a quarterly dividend of $0.50 to be paid on December 2nd.

Alpine Woods Capital Investors LLC lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 53.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,725 shares of the company's stock after selling 10,170 shares during the period. Alpine Woods Capital Investors LLC's holdings in Zoetis were worth $1,361,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent analyst reports. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, Zoetis presently has an average rating of "Hold" and a consensus target price of $196.71.

Zoetis Price Performance

NYSE ZTS opened at $142.29 on Tuesday. The company has a 50-day moving average price of $149.04 and a two-hundred day moving average price of $154.19. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The stock has a market cap of $63.06 billion, a price-to-earnings ratio of 24.49, a price-to-earnings-growth ratio of 2.26 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The business's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's dividend payout ratio is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.